ESR1 and triple-negative breast carcinoma: Although these cells need to be confirmed in the tumor tissue slides, increasing evidence points toward neutrophils and a higher neutrophils/lymphocyte ratio as markers of disease aggressiveness in ER- and HER2-negative breast cancers [53] as well as in triple-negative breast cancers [54] and response to chemotherapy [55], endocrine therapy [56] or trastuzumab treatment [57].